Ang Li Lab

Ang Li Lab Trainee Publications

Master
Content
  • Shang H, Jiang JY, Guffey D, Novoa F, Bandyo R, Ma S, Li A. Natural History of Cancer-Associated Splanchnic Vein Thrombosis. J Thromb Haemost. 2024:S1538-7836(24)00060-6. doi: 10.1016/j.jtha.2024.01.019. PMID: 38309433. [original work]
  • Kim R#, Li A#, Park K, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events Comparing East Asians with Westerners. JACC: Asia, 2023, ISSN 2772-3747. https://doi.org/10.1016/j.jacasi.2023.07.008 [#co-first authors, original work]
  • Ma S, Bhar S, Guffey D, Kim RB, Jamil M, Amos CI, Lee SJ, Hingorani SR, Sartain SE#, Li A#. Prospective clinical and biomarker validation of the ASTCT consensus definition for transplant-associated thrombotic microangiopathy (TA-TMA). Transplant Cell Ther 2023 Aug 17;S2666-6367(23)01472-0. doi: 10.1016/j.jtct.2023.08.015. PMID: 37597686 [#co-senior authors, original work]
  • Avery J, Guffey D, Ma S, Basom R, Lee SJ, Garcia DA, Rojas Hernandez CM, Li A#, Martens KL#. Risks factors and outcomes for isolated catheter-related deep venous thrombosis in patients undergoing allogeneic hematopoietic stem cell transplantation. Thromb Res 2023;229:1-6. PMID: 37356171. PMCID: PMC10527315 [#co-senior authors, original work]
  • Martens KL#, Li A#, La J, May SB, Swinnerton KN, Tosi H, Elbers DC, Do NV, Brophy MT, Gaziano JM, Lotfollahzadeh S, Chitalia V, Ravid K, Fillmore NR. Epidemiology of venous thromboembolism in patients with solid and hematologic malignancies in the United States. JAMA Netw Open 2023;6(6):e2317945. PMID: 37306999. PMCID: PMC10261992 [#co-first authors, original work]
  • Zhang Z, Hong W, Wu Q, Tsavachidis S, Li JR, Amos CI, Cheng C, Sartain SE, Afshar-Kharghan V, Dong JF, Bhatraju P, Martin PJ, Makar RS, Bendapudi PK, Li A. Pathway-driven rare germline variants associated with transplant-associated thrombotic microangiopathy (TA-TMA). Thromb Res 2023;225:39-46. PMID: 36948020. PMCID: PMC10147584 [original work]
  • Dima D#, Li A#, Granat LM, Dhillon P, Chamseddine F, Wei W, Samaras CJ, Valent J, Anwer F and Khouri J. External Validation of the SAVED Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs. Br J Haematol 2023;201(2):280-284. PMID: 36604838 [#co-first authors, original work]
  • da Costa WL, Guffey D, Oluyomi A, Bandyo R, Rosales O, Wallace CD, Granada C, Riaz N, Fitzgerald M, Garcia DA, Carrier M, Amos CI, Flowers CR, Li A. Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. Am J Hematol 2022;97(8):1044-1054. PMID: 35638475 [original work]
  • Li A#, Martens KL#, Nguyen D, Basom R, Rondon G, Jin S, Young E, Amos CI, Lee SJ, Davis C, Garcia DA, Champlin R, Shpall E, Kebriaei P#, Rojas Hernandez CM#. External Validation of the HIGH-2-LOW Model: A Predictive Score for Venous Thromboembolism after Allogeneic Transplant. Am J Hematol 2022;97(6):740-748. PMID: 35266218 [original work]
  • Van Benschoten V, Roy C, Gupta R, Ouellette L, Hingorani S, Li A. Incidence and risk factors of transplant-associated thrombotic microangiopathy (TA-TMA): a systematic review and meta-analysis. Transplant Cell Ther 2022;28(5):266.e1-266.e8. PMID: 35042011 [original work]
  • Martens KL, Amos CI, Hernandez CR, Kebriaei P, da Costa WL, Basom R, Davis C, Kesten M, Carrier M, Garcia DA, Lee SJ, Li A. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol 2021;96(9):1137-1146. PMID: 34097772. [original work]
  • Martens KL, da Costa Jr WL, Amos CI, Davis C, Kesten M, Lee SJ, Zakai NA, Garcia DA, Li A. HIGH-2-LOW Risk Model to Predict Venous Thromboembolism in Allogeneic Transplant Patients After Platelet Engraftment. Blood Adv 2021;5:167-175. PMID: 33570631; PMCID: PMC7805312 [original work]
  • Desai A, Gupta R, Advani S, Ouellette L, Kuderer NM, Lyman GH, Li A. Mortality in Hospitalized Patients with Cancer and COVID-19: A Systematic Review and Meta-Analysis of Cohort Studies. Cancer 2020;127(9):1459-1468. PMID: 33378122. [original work]
  • Khalighi PR, Martens KL, White AA, Li S, Silgard E, Frieze D, Garcia DA, Li A. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. J Oncol Pharm Pract 2020;26(3)529-535. PMID: 31167612 [original work]
  • Martens KL, Khalighi PR, Li S, White AA, Silgard E, Frieze D, Estey E, Garcia DA, Hingorani S, Li A. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res 2020;89:106298. PMID: 31945598 [original work]